Selective serotonin reuptake inhibitors and suicide: Is the evidence, as with beauty, in the eye of the beholder?

Psychotherapy and Psychosomatics

Volumn 72, Issue 6, 2003, Pages 293-299

  Balon, Richard ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UPC Jefferson   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; FLUOXETINE; FLUVOXAMINE; MIANSERIN; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

AGITATION; AKATHISIA; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; EDITORIAL; HUMAN; INCIDENCE; MAJOR DEPRESSION; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; PROPAGANDA; RATING SCALE; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUICIDAL BEHAVIOR; SUICIDE; TREATMENT WITHDRAWAL;

AKATHISIA, DRUG-INDUCED; CAUSE OF DEATH; CLINICAL TRIALS; DEPRESSIVE DISORDER; EPIDEMIOLOGIC STUDIES; HUMANS; PROPAGANDA; RISK; SEROTONIN UPTAKE INHIBITORS; SUICIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0142089151     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073025     Document Type: Editorial

References (43)

1. Healy D: Lines of evidence on the risk of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003;72:71-79.
2. Rihmer Z: Do SSRIs increase the risk of suicide among depressives even if they are taking only placebo? Psychother Psychosom 2003;72:357-358.
3. Benazzi F: Do SSRIs cause suicide? Psychother Psychosom 2003;72:358-359.
4. Healy D: Reply to Rihmer and Benazzi. Psychother Psychosom 2003;72:360-361.
5. Fava G: Long-term treatment with antidepressant drugs: The spectacular achievements of propaganda. Psychother Psychosom 2002;71:127-132.
6. Chomsky N: Media Control: The Spectacular Achievements of Propaganda. New York, Seven Stories, 1997.
7. Healy D: The antidepressant drama; in Weissman MM (ed): Treatment of Depression. Washington, American Psychiatric Press, 2001, pp 7-34.
8. Lane RM: SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment. J Psychopharmacol 1998;12:192-214.
9. Khan A, Warner H, Brown A: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-317.
10. Storosum JG, van Zwieten BJ, van den Brink W, Gersons BPR, Broekmans AW: Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 2001;158:1271-1275.
11. Laughren TP: The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: An FDA perspective. Eur Psychiatry 2001;16:418-423.
12. Khan A, Khan SR, Leventhal RM, Brown WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration database. Int J Neuropsychopharmacol 2001;4:113-118.
13. Kraemer HC: Statistical analysis to settle ethical issues? Arch Gen Psychiatry 2000;57:327-328.
14. Hirschfeld RMA: Suicide and antidepressant treatment. Arch Gen Psychiatry 2000;57:325-326.
15. Leber P: Placebo controls: No news is good news. Arch Gen Psychiatry 2000;57:319-320.
16. Asleigh EA, Fesler FA: Fluoxetine and suicidal preoccupation. Am J Psychiatry 1992;149:1750.
17. Teicher MH, Glod C, Cole JO: Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210.
18. Fava M, Rosenbaum JF: Suicidality and fluoxetine: Is there a relationship? J Clin Psychiatry 1991;52:108-111.
19. American College of Neuropsychopharmacology: Suicidal behavior and psychotropic medication. Accepted as a consensus statement by the ACNP Council, March 2, 1992. Neuropsychopharmacology 1993;8:177-183.
20. Warshaw MG, Keller MB: The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psychiatry 1996;57:158-166.
21. Leon AC, Keller MB, Warshaw MG, Mueller TI, Solomon DA, Coryell W: Prospective study of fluoxetine treatment and suicidal behavior in affective ill subjects. Am J Psychiatry 1999;156:195-201.
22. Fisher S, Bryant SG, Kent TA: Postmarketing surveillance by patient self-monitoring: Trazodone versus fluoxetine. J Clin Psychopharmacol 1993;13:235-242.
23. Fisher S, Kent TA, Bryant SG: Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995;56:288-296.
24. Donovan S, Kelleher MJ, Lambourn J, Foster T: The occurrence of suicide following the prescription of antidepressant drugs. Arch Suicide Res 1999;5:181-192.
25. Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K, Gardner D, Faulding J, Madeley R: Deliberate self-harm and antidepressant drugs: Investigation of a possible link. Br J Psychiatry 2000;177:551-556.
26. Jick SS, Dean AD, Jick H: Antidepressants and suicide. BMJ 1995;310:215-218.
27. Hagnell O, Lanke J, Rorsman B: Suicide rates in the Lundby study: Mental illness as a risk factor for suicide. Neuropsychobiology 1981;7:248-253.
28. Simon GE, Von Korff M: Suicide mortality among patients treated for depression in an insured population. Am J Epidemiol 1998;147:155-160.
29. Isacsson G: Suicide prevention - a medical breakthrough. Acta Psychiatr Scand 2000;102:113-117.
30. Barbui C, Campomori A, D'Avanzo B, Negri E, Garattini S: Antidepressant drug use in Italy since the introduction of the SSRIs: National trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999;34:152-156.
31. Hotopf M, Lewis G, Normand C: Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996;168:404-409.
32. Healy D: Emergence of antidepressant induced suicidality. Prim Care Psychiatry 2000;6:23-28.
33. Nafziger AN, Bertino JS, Goss-Bley AI, Kashuba ADM: Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. J Clin Psychiatry 1999;60:187-190.
34. Gelfin Y, Gorfine M, Lerer B: Effects of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psychiatry 1998;155:290-292.
35. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, Terpstra J, Turner RA, Reus VI: Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155:373-379.
36. Khan A, Khan S, Kolts R, Brown WA: Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: Analysis of FDA reports. Am J Psychiatry 2003;160:790-792.
37. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P: Association between antidepressant prescribing and suicide in Australia, 1991-2000: Trend analysis. BMJ 2003;326:1008-1011.
38. Rihmer Z, Belso N, Kalmar S: Antidepressants and suicide prevention in Hungary. Acta Psychiatr Scand 2001;103:238-239.
39. Szanto K, Mulsant BH, Houck P, Dew MA, Reynolds CF: Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003;60:610-617.
40. Pohl R, Yeragani VK, Balon R, Lycaki H: The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49:100-104.
41. Qin P, Agerbo E, Mortensen PB: Suicide risk in relation to socioeconomic, demographic, psychiatric, and familial factors: A national register-based study of all suicides in Denmark, 1981-1997. Am J Psychiatry 2003;160:765-772.
42. Lambert G, Reid C, Kaye D, Jennings G, Esler M: Increased suicide rate in the middle-aged and its association with hours of sunlight. Am J Psychiatry 2003;160:793-795.
43. Malone KM, Waternaux C, Haas GL, Cooper TB, Li S, Mann JJ: Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry 2003;160:773-779.